Fidēs, a newly launched imaging contract research organisation (iCRO), has announced its formal entry into the clinical research market with a focus on early-phase drug development. The company debuted at the 2026 SCOPE Summit in January, positioning itself as a science-first partner for biopharma sponsors working in scientifically demanding therapeutic areas.
Epigenica AB has introduced its EpiFinder™ Analysis Service, a fully managed, end-to-end platform designed to deliver fast, reproducible epigenomic data to researchers across academia, pharma, and clinical settings.
ProBioGen, the Berlin-based contract development and manufacturing organisation (CDMO), has introduced CMC Navigator™, a structured framework comprising four defined service models aimed at supporting biopharmaceutical companies through the key stages of protein Chemistry, Manufacturing and Controls (CMC) development.
Carterra Inc. has launched the Vega™ High-Throughput Surface Plasmon Resonance (HT-SPR) instrument, the first 48-channel SPR platform to reach the market. The system is designed to address a long-standing throughput bottleneck in label-free binding analysis, offering a 12-fold increase in throughput compared to the current market-leading system across small and large molecule discovery workflows.
Agilent Technologies has introduced the S540MD Slide Scanner System, a whole slide imaging (WSI) platform designed for high-throughput digital pathology workflows in clinical laboratories.
Biotech Fluidics has introduced the DEGASi® Flat Film in-line degasser, a system that replaces conventional tubular membranes with specialised flat film technology to remove dissolved gases from liquid streams. The design is aimed at instrument developers, manufacturers, and clinical and research laboratories requiring reliable degassing across a broad range of solvents and flow conditions.
DiaSys successfully introduced Total bile acids 21 FS to determine total bile acids (TBA) in serum. Now, without altering the reagent composition and the highly sensitive enzymatic cycling method, the scope of the test has been expanded to detect TBA in human stool samples.
TRIMERO Diagnostics is delighted to announce that we have begun to manufacturing our IgD Immunoglobulin assays, in accordance with the requirements of the Regulation (EU) 2017/746 on in vitro diagnostic medical devices, and will therefore be IVDR Certified.
Revvity has announced the launch of Signals Xynthetica, a Models-as-a-Service AI platform designed to accelerate molecular and materials discovery by integrating computational design with experimental validation within a unified environment.
Touchlight has expanded its mbDNA (megabulb DNA) platform with three new circular DNA architectures designed to enhance gene editing and therapeutic development. The company says that sscDNA, hsscDNA, and dscDNA constructs now complement its existing mbDNA technology, offering researchers customisable solutions for gene insertion and expression applications.
March 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.